Keygene N.V. in Association for MolecularPathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013)
An amicus brief filed on behalf of Keygene N.V. in Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013) in support of Myriad Genetics. The Supreme Court held that naturally occurring DNA sequences cannot be patented. The Court unanimously ruled that genes and the information they encode are not patent eligible simply because they have been isolated from the surrounding genetic material.
Dr. Peet also assisted Keygene N.V. in securing U.S. patents with claims directed to use of next-generation DNA sequencing to identify genetic variations in plants. Based on these patents, Keygene sued Floragenex for patent infringement resulting in a negotiated settlement in which Floragenex agreed
to pay Keygene royalties for use of the patented technologies.